Bungay becomes CEO at Imophoron, Garzoni transitions to CSO

Imophoron Ltd. named Richard Bungay as CEO, succeeding founding CEO Fred Garzoni who will become CSO. Bungay was CEO at AIM-listed Diurnal Group plc, and led the sale of the company to Neurocrine Biosciences Inc. (NASDAQ:NBIX). Imophoron is developing vaccines using ADDomer, its nanoparticle platform. 

Genetic medicine company Code Biotherapeutics Inc. hired Alex Tracy as CTO. Tracy was CTO at BridgeBio Gene Therapy, a BridgeBio Pharma Inc. (NASDAQ:BBIO) company, and previously led technical, regulatory and quality assurance at Istari Oncology Inc...